---
title: ER2 Frailty Levels and Incident Adverse Health Events in Older Community Dwellers
nct_id: NCT04431986
overall_status: UNKNOWN
sponsor: Jewish General Hospital
study_type: OBSERVATIONAL
primary_condition: Frailty
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04431986.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04431986"
ct_last_update_post_date: 2020-06-16
last_seen_at: "2026-05-12T07:04:21.714Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# ER2 Frailty Levels and Incident Adverse Health Events in Older Community Dwellers

**Official Title:** Association Between Emergency Room Evaluation and Recommendations Tool (ER2) Frailty Levels and Incident Adverse Health Events in Older Community Dwellers: Results of the NuAge Study

**NCT ID:** [NCT04431986](https://clinicaltrials.gov/study/NCT04431986)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 1741
- **Lead Sponsor:** Jewish General Hospital
- **Conditions:** Frailty, Emergencies, Aging
- **Start Date:** 2020-09-01
- **Completion Date:** 2021-09-01
- **CT.gov Last Update:** 2020-06-16

## Brief Summary

Older adults' health and functional status are heterogeneous because of the various cumulative effects of chronic diseases and physiologic decline, contributing to a vicious cycle of increased frailty 1-4. Thanks to advances in medicine and hygiene, a growing number of older adults spend more years with a greater range of chronic diseases causing disability but not mortality 5. Health systems need to face this new challenge 4,5. Quantification of frailty and its association with the occurrence of incident adverse health events (i.e., functional decline, unplanned hospitalizations) is crucial to understand how health systems may efficiently respond to this situation 6. This study aims to examine the association of the ER2 tool score and its stratification in three levels for incident adverse health events in older community dwellers and to compare this association with three validity frailty indexes which are the Cardiovascular Health Study (CHS) frailty index, Study of Osteoporotic Fracture (SOF) index and Rockwood frailty index.

## Eligibility

- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* All enrolled participants of NuAge Study who agreed to be part of the NuAge Database and Biobank for future research purposes

Exclusion Criteria:

* Missing data
* Participants' refusal to use their data for a purpose not identified during their recruitment.
```

## Arms

- **NuAge participants** — All Individuals of the NuAge study who agreed to be part of the NuAge Database for future research purposes

## Interventions

- **No intervention: secondary use of a database** (OTHER) — Statistical analyses

## Primary Outcomes

- **ER2** _(time frame: 4 years)_ — 6-item questionnaire determining a stratification of frailty risk in three levels (Low, moderate, high)
- **SOF index** _(time frame: 4 years)_ — index with 3 items determining a level of frailty from 0 (patient is vigorous) to 1 (patient is pre-frail)
- **CHS index** _(time frame: 4 years)_ — index with 5 items determining a level of frailty from 0 component positive (patient is vigorous), 1 or 2 positive components (patient is in an intermediate stage) to 3 or more positive components (patients is frail)
- **Rockwood index** _(time frame: 4 years)_ — index determining a level of frailty from 0 to 17 (less than 5: patient is vigorous, between 6 and 11 patient is apparently vulnerable and above 12 patient is in severe frailty)
- **Physical functional decline** _(time frame: 4 years)_ — annual variation of physical functional score available in the Nuage database
- **Falls** _(time frame: 4 years)_ — presence or absence of falls, information available in the Nuage database
- **Hospitalizations** _(time frame: 4 years)_ — presence or absence of hospitalizations, information available in the Nuage database
- **Mortality** _(time frame: 4 years)_ — death of the participant, information available in the Nuage database

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04431986.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04431986*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*